{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T22:24:40Z","timestamp":1773354280123,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,4,17]],"date-time":"2014-04-17T00:00:00Z","timestamp":1397692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,4,17]],"date-time":"2014-04-17T00:00:00Z","timestamp":1397692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1038\/jhh.2014.27","type":"journal-article","created":{"date-parts":[[2014,4,17]],"date-time":"2014-04-17T09:25:07Z","timestamp":1397726707000},"page":"28-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension"],"prefix":"10.1038","volume":"29","author":[{"given":"C S","family":"Oxlund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Cangemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J E","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I A","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Gram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Schousboe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Tarnow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W S","family":"Argraves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L M","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,17]]},"reference":[{"issue":"9841","key":"BFjhh201427_CR1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0140-6736(12)60987-8","volume":"380","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Cushman WC . Diabetes and hypertension: the bad companions. Lancet 2012; 380 (9841): 601\u2013610.","journal-title":"Lancet"},{"key":"BFjhh201427_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/1475-2840-11-127","volume":"11","author":"KK Naka","year":"2012","unstructured":"Naka KK, Papathanassiou K, Bechlioulis A, Kazakos N, Pappas K, Tigas S et al. Determinants of vascular function in patients with type 2 diabetes. Cardiovasc Diabetol 2012; 11: 127.","journal-title":"Cardiovasc Diabetol"},{"key":"BFjhh201427_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jama.2010.884","volume":"304","author":"RM Cooper-DeHoff","year":"2010","unstructured":"Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL et al. Tight blood pressure control and cardiovascular outcomes among antihypertensive patiets with diabets and coronary disease. JAMA 2010; 304: 61\u201368.","journal-title":"JAMA"},{"issue":"25","key":"BFjhh201427_CR4","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","volume":"117","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117 (25): e510\u2013e526.","journal-title":"Circulation"},{"issue":"6","key":"BFjhh201427_CR5","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","volume":"57","author":"J Vaclavik","year":"2011","unstructured":"Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57 (6): 1069\u20131075.","journal-title":"Hypertension"},{"key":"BFjhh201427_CR6","first-page":"89","volume":"50","author":"M Briet","year":"2013","unstructured":"Briet M, Schriffrin EL . Vascular actions of aldosterone. J Vacs Res 2013; 50: 89\u201399.","journal-title":"J Vacs Res"},{"issue":"2","key":"BFjhh201427_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2337\/db12-0905","volume":"62","author":"SB Bender","year":"2013","unstructured":"Bender SB, McGraw AP, Jaffe IZ, James RS . Mineralocorticoid receptor-mediated vascular insulin resistance. An early contributor to diabetes-related vascular disease. Diabetes 2013; 62 (2): 313\u2013319.","journal-title":"Diabetes"},{"key":"BFjhh201427_CR8","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1373\/clinchem.2011.162966","volume":"57","author":"C Cangemi","year":"2011","unstructured":"Cangemi C, Skov V, Poulsen MK, Funder J, Twal WO, Gall MA et al. Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. Clin Chem 2011; 57: 1556\u20131565.","journal-title":"Clin Chem"},{"key":"BFjhh201427_CR9","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1083\/jcb.111.6.3155","volume":"111","author":"WS Argraves","year":"1990","unstructured":"Argraves WS, Tran H, Burgess WH, Dickerson K . Fibulin is an extracellular matrix and plasma glycoprotein with repeated domain structure. J Cell Biol 1990; 111: 3155\u20133164.","journal-title":"J Cell Biol"},{"key":"BFjhh201427_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/0092-8674(89)90097-4","volume":"58","author":"WS Argraves","year":"1989","unstructured":"Argraves WS, Dickerson K, Burgess WH, Ruoslahti E . Fibulin, a novel protein that interacts with the fibronectin receptor beta subunit cytoplasmic domain. Cell 1989; 58: 623\u2013629.","journal-title":"Cell"},{"key":"BFjhh201427_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1475-2840-11-15","volume":"11","author":"V Skov","year":"2012","unstructured":"Skov V, Knudsen S, Olesen M, Hansen ML, Rasmussen LM . Global gene expression profiling displays a network of dysregulated genes in non-atherosclerotic arterial tissue from patients with type 2 diabetes. Cardiovasc Diabetol 2012; 11: 15.","journal-title":"Cardiovasc Diabetol"},{"key":"BFjhh201427_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1475-2840-12-6","volume":"12","author":"A Stolze","year":"2013","unstructured":"Stolze A, Bladbjerg EM, Sidelmann JJ, Diederichen ACP, Mickley H, Nybo M et al. Plasma concentrations of extracellular matrix fibulin-1 are related to cardiovascular risk markers in chronic kidney disease and diabetes. Cardiovasc Diabetol 2013; 12: 6.","journal-title":"Cardiovasc Diabetol"},{"key":"BFjhh201427_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/1475-2840-12-107","volume":"12","author":"E Laugesen","year":"2013","unstructured":"Laugesen E, H\u00f8yrem P, Christiansen JS, Kundsen ST, Hansen KW, Argaves WS et al. Plasma levels of the arterial wall protein fibulin-1 are associated with carotid-femoral pulse wave velocity; a cross-sectional study. Cardiovasc Diabetol 2013; 12: 107.","journal-title":"Cardiovasc Diabetol"},{"key":"BFjhh201427_CR14","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1097\/HJH.0b013e3283638b1a","volume":"31","author":"CS Oxlund","year":"2013","unstructured":"Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA . Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 DM: a double blind randomized clinical trial. J Hypertens 2013; 31: 2094\u20132102.","journal-title":"J Hypertens"},{"key":"BFjhh201427_CR15","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannand F, Remme WJ, Codt R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality, in patients with severe heart failure. Randomized Adalactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709\u2013717.","journal-title":"N Engl J Med"},{"key":"BFjhh201427_CR16","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1096\/fj.13-228312","volume":"27","author":"V Druppel","year":"2013","unstructured":"Druppel V, Kusche-Vihrog K, Grossmann C, Gekle M, Kadpzak B, Brand E et al. Long-term application of aldosteron antagonist spironolactone prevents stiff endothelial cell syndrome. FASEB J 2013; 27: 3652\u20133659.","journal-title":"FASEB J"},{"issue":"4","key":"BFjhh201427_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1751-7176.2011.00449.x","volume":"13","author":"WA Hsueh","year":"2011","unstructured":"Hsueh WA, Wyne K . Renin-angiotensin-aldosterone system in diabetes and hypertension. J Clin Hypertens (Greenwich) 2011; 13 (4): 224\u2013237.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"BFjhh201427_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ajh.2011.245","volume":"25","author":"H Shibata","year":"2012","unstructured":"Shibata H, Itoh H . Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens 2012; 25 (5): 514\u2013523.","journal-title":"Am J Hypertens"},{"key":"BFjhh201427_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/43.4.7534784","volume":"43","author":"EF Roak","year":"1995","unstructured":"Roak EF, Keene DR, Haudenschild CC, Godyna S, Little CD, Argaves WS . The association of human fibulin-1 with elastic fibers: an immunohistological, ultrastructural, and RNA study. J Histochem Cytochem 1995; 43: 401\u2013411.","journal-title":"J Histochem Cytochem"},{"issue":"2","key":"BFjhh201427_CR20","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ydbio.2008.04.029","volume":"319","author":"MA Cooley","year":"2008","unstructured":"Cooley MA, Kem CB, Fresco VM, Wessels A, Thompson RP, McQuinn TC et al. Fibulin-1 is required for morphogenesis of neural crest-derived structures. Dev Biol 2008; 319 (2): 336\u2013345.","journal-title":"Dev Biol"},{"issue":"6","key":"BFjhh201427_CR21","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.juro.2012.12.107","volume":"189","author":"A Nehra","year":"2013","unstructured":"Nehra A, Jackson G, Miner M, Billups KL, Burnett AL, Buvat J et al. Diagnosis and treatment of erectile dysfunction for reduction of cardiovascular risk. J Urol 2013; 189 (6): 2031\u20132038.","journal-title":"J Urol"},{"issue":"suppl","key":"BFjhh201427_CR22","doi-asserted-by":"publisher","first-page":"52M","DOI":"10.1016\/j.amjcard.2005.10.006","volume":"95","author":"A Guay","year":"2005","unstructured":"Guay A . Relation of endothelial cell function to erectile dysfunction: implications for treatment. Am J Cardiol 2005; 95 (suppl): 52M\u201356M.","journal-title":"Am J Cardiol"},{"key":"BFjhh201427_CR23","doi-asserted-by":"publisher","first-page":"627278","DOI":"10.1155\/2012\/627278","volume":"2012","author":"V Javaroni","year":"2012","unstructured":"Javaroni V, Neves MF . Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment. Int J Hypertens 2012; 2012: 627278.","journal-title":"Int J Hypertens"},{"key":"BFjhh201427_CR24","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/j.1464-410X.2008.08251.x","volume":"103","author":"I Konvanecz","year":"2009","unstructured":"Konvanecz I, Nolazco G, Ferrini MG, Toblli JE, Heydarkhan S, Vernet D et al. Early onset if fibrosis within the arterial media in a rat model of type 2 diabetes mellitus with erectiledysfunction. BJU Int 2009; 103: 1396\u20131404.","journal-title":"BJU Int"},{"key":"BFjhh201427_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/jhh.2011.9","volume":"26","author":"E Laugesen","year":"2012","unstructured":"Laugesen E, Rossen NB, Poulsen PL, Hansen KW, Ebbeh\u00f8j E, Knudsen ST . Pulse pressure and systolic night-day ratio interact in prediction of macrovascular disease in patients with type 2 diabetes mellitus. J Hum Hypertens 2012; 26: 164\u2013170.","journal-title":"J Hum Hypertens"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/jhh201427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201427","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T20:08:55Z","timestamp":1647547735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh201427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,17]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["BFjhh201427"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2014.27","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,17]]},"assertion":[{"value":"12 November 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}